Revvity, Inc. (RVTY) Stock Analysis
Is RVTY a good investment?
Revvity, Inc. (RVTY) has a Plutrex AI rating of 33.0/100 as of October 10, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: Balance sheet fortress: D/E of 0.38 (40.6% below industry average 0.64), $1.02B cash position, and $559M annual FCF — zero near-term financial distress risk with capacity for opportunistic M&A/buybacks without leveraging up. Main concern: Catastrophic valuation disconnect: P/E of 73.22x (96.5% premium to industry 37.26x), PEG of 8.60 (38.9% premium to already-expensive industry 6.19), stock trading 2.7% ABOVE analyst consensus target of $150.00 — FCF-based intrinsic value of $80-100/share implies 35-48% downside from current price of $154.18.
Investment Summary
RVTY (Revvity) is a significantly overvalued Medical Diagnostics & Research company trading at $154.18 against an analyst consensus target of $150.00 — meaning the stock is already 2.7% ABOVE where even optimistic sell-side analysts think it should be. The core investment thesis is dominated by one overwhelming problem: a P/E of 73.22x against historical earnings growth of just 1.2% and projected forward EPS growth of 9.9%. This produces a PEG ratio of 8.60 — nearly 9x the value-investor threshold of 1.0 and 4x the growth-investor threshold of 2.0. Relative to its Medical Diagnostics peers, RVTY trades at a 96.5% P/E premium (73.22x vs. industry 37.26x) while delivering forward growth that is 47.8% BELOW the peer average (9.88% vs. 18.91%). ROE of 3.21% is 69.4% below the industry average of 10.49%. The one genuine bright spot is FCF of $559M (driven by non-cash amortization masking thin net margins of 8.2%), a strong $1.02B cash balance, and D/E of 0.38 (40.6% below peers). News is legitimately positive — CE-IVDR-certified T1D newborn screening launch in Europe, GLP-1 research exposure, and an Investor Day — but positive news at this valuation is irrelevant; the 40%+ gap between current price and FCF-based intrinsic value ($80-100/share) cannot be closed by product launches. This remains a SELL.
Key Strengths
- Balance sheet fortress: D/E of 0.38 (40.6% below industry average 0.64), $1.02B cash position, and $559M annual FCF — zero near-term financial distress risk with capacity for opportunistic M&A/buybacks without leveraging up
- Gross margin of 48.19% exceeds industry average of 41.69% by 656 bps (+15.7%), indicating genuine pricing power in diagnostics instrumentation with recurring reagent/consumable streams providing durable revenue quality
- Real product optionality in growing markets: CE-IVDR-certified newborn T1D screening kit expands European addressable market; GLP-1/metabolic disease research exposure through human cell models represents credible if modest tailwind
Key Concerns
- Catastrophic valuation disconnect: P/E of 73.22x (96.5% premium to industry 37.26x), PEG of 8.60 (38.9% premium to already-expensive industry 6.19), stock trading 2.7% ABOVE analyst consensus target of $150.00 — FCF-based intrinsic value of $80-100/share implies 35-48% downside from current price of $154.18
- Structural growth laggard with no credible acceleration evidence: Revenue growth 1.3% vs. industry 16.9% (92.3% below peers), earnings growth 1.2% vs. industry 22.8% (94.7% below peers), ROE 3.21% vs. industry 10.49% (69.4% below peers) — the company demands the sector's highest valuation premium while delivering its worst growth metrics, a fundamentally irrational risk/reward
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Profitability is structurally weak despite a respectable gross margin of 48.19% (vs. industry 41.69%). The problem is the collapse from gross profit to net income: operating margin of 17.05% implies ~31 percentage points consumed by R&D/SG&A/restructuring, and net margin of 8.18% (vs. industry 11.27%) shows a further 9-point compression from interest expense and intangible amortization on the large acquired asset base. This cascade produces ROE of 3.21% — barely above risk-free rates and 69.4% below the industry average of 10.49%. Growth is the company's most critical failure: revenue growth of 1.3% (vs. industry 16.9%) and earnings growth of 1.2% (vs. industry 22.8%) represent near-complete stagnation. Forward EPS of 9.88% next year and 8.51% 5-year CAGR are below the industry averages of 18.91% and 12.66% respectively. Valuation is extreme: P/E of 73.22x is appropriate for 30-40% growth companies, not 8-10% growers. PEG of 8.60 vs. industry 6.19 — RVTY is expensive even relative to an already-expensive sector. D/E of 0.38 is the healthiest balance sheet metric, and FCF of $559M is genuine cash generation, but applying a generous 18x FCF multiple yields ~$10B enterprise value — likely well below current market cap implying ~$154/share. The analyst consensus of $150.00 is itself below current price, confirming broad sell-side recognition of overvaluation.
News Sentiment
Revvity is making real moves in the diagnostics world — but whether those moves are enough to justify its sky-high stock price is another question entirely. The company recently launched a CE-IVDR-certified automated kit for detecting Type 1 Diabetes in newborns and young children across Europe (headline: 'RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection' and 'Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes'). This is genuinely meaningful: T1D often goes undetected until serious symptoms emerge, and early diagnosis could transform patient outcomes. For Revvity, it opens doors to thousands of European labs and clinics that previously couldn't afford or operationally support T1D screening. The company is also positioning itself to benefit from the GLP-1 drug boom — pharmaceutical giants developing Ozempic-style metabolic disease therapies need human cell models for research, and Revvity is building that capability. An upcoming Investor Day (headline: 'Revvity to Host Investor Day') signals management is eager to tell this growth story directly to Wall Street. One analyst even upgraded the stock to Buy (headline: 'Revvity (RVTY) Upgraded to Buy'). The challenge? Revvity's stock already trades at 73 times earnings — nearly double what most of its competitors command — while growing revenues at just 1.3% annually. The new diabetes kit and GLP-1 exposure are real opportunities, but they'd need to deliver explosive growth just to justify the current price tag.
Risk Assessment
PRIMARY RISK TO SHORT THESIS: Momentum continuation — RVTY has risen from $143.45 (prior report, 14 days ago) to $154.18 today (+7.5% in two weeks) despite zero fundamental improvement. Momentum-driven names can remain irrational longer than expected. An Investor Day event could trigger a fresh re-rating if management presents a credible acceleration story. SECONDARY RISK: Acquisition or buyout premium — the $1.02B cash and conservative D/E make RVTY a potential target, though the $73x P/E makes a buyout premium nearly impossible to justify. DOWNSIDE SCENARIO (base case): Multiple compression to 25-30x P/E on $2.10/share earnings = $52-63/share (-59-66% from current). BEAR CASE: If forward EPS estimates are cut (which the historical 1.2% earnings growth record makes plausible), the stock could trade toward FCF-based intrinsic value of $80-100. MITIGATION: For existing holders, implement a trailing stop at 7-8% below current price (~$142-143) to capture any remaining momentum while limiting downside exposure.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is RVTY a halal stock?
No, Revvity, Inc. (RVTY) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for RVTY?
Revvity, Inc. (RVTY) has a Plutrex AI rating of 33.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is RVTY a good investment?
According to Plutrex AI, RVTY has a Sell rating (33.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in RVTY?
US stocks like RVTY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in RVTY?
Plutrex AI identifies the main risks for RVTY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.